The model included the following covariates: age, most recent hemoglobin A1c (if available), overweight/obesity status, body mass index (BMI), hypertension, ischemic heart disease, obstructive sleep apnea, hyperlipidemia, hypercholesterolemia, and prior therapy with antidiabetic agents (including sodium-glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas, metformin, insulins, and other blood glucose-lowering drugs), as shown in Supplementary Table 1
You might also like Hyssinol $35.99
Obesity has impacts on cardiovascular disease outcomes through increased risk of coronary artery disease, heart failure (more prominent with preserved ejection fraction), cardiac arrhythmias (most significantly atrial fibrillation), sudden death, and venous thromboembolism [7]
Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5non-coding region
